Literature DB >> 15996084

Treatment of orbital myositis with adalimumab (Humira).

Alexa B Adams1, Michael Kazim, Thomas J A Lehman.   

Abstract

Adalimumab is a fully humanized IgG1 monoclonal antibody to tumor necrosis factor-a. We describe 2 patients (17 and 13 years of age) with refractory, steroid-dependent, recurrent nonspecific orbital myositis not controlled with standard immunosuppressive medications. Both improved with adalimumab treatment, allowing reduction in corticosteroid dosage without disease flare.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15996084

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  14 in total

1.  Factors associated with multiple recurrences of nonspecific orbital inflammation aka orbital pseudotumor.

Authors:  Puneet S Braich; Robin K Kuriakose; Naveen S Khokhar; Jared C Donaldson; Timothy J McCulley
Journal:  Int Ophthalmol       Date:  2017-06-20       Impact factor: 2.031

2.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 3.  Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.

Authors:  Piergiorgio Neri; Manuela Zucchi; Pia Allegri; Marta Lettieri; Cesare Mariotti; Alfonso Giovannini
Journal:  Int Ophthalmol       Date:  2011-02-02       Impact factor: 2.031

Review 4.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 5.  Biologic agents in the management of inflammatory eye diseases.

Authors:  Kira Michalova; Lyndell Lim
Journal:  Curr Allergy Asthma Rep       Date:  2008-07       Impact factor: 4.806

6.  Adalimumab in the therapy of uveitis in childhood.

Authors:  Sabine Biester; Christoph Deuter; Hartmut Michels; Renate Haefner; Jasmin Kuemmerle-Deschner; Deshka Doycheva; Manfred Zierhut
Journal:  Br J Ophthalmol       Date:  2006-10-11       Impact factor: 4.638

Review 7.  Pharmacotherapy of scleritis: current paradigms and future directions.

Authors:  Robert M Beardsley; Eric B Suhler; James T Rosenbaum; Phoebe Lin
Journal:  Expert Opin Pharmacother       Date:  2013-02-21       Impact factor: 3.889

8.  Adalimumab (humira™) in ophthalmology: a review of the literature.

Authors:  Piergiorgio Neri; Marta Lettieri; Cinzia Fortuna; Manuela Zucchi; Mara Manoni; Silvia Celani; Alfonso Giovannini
Journal:  Middle East Afr J Ophthalmol       Date:  2010-10

9.  Adalimumab for Ocular Inflammation.

Authors:  Khayyam Durrani; John H Kempen; Gui-Shuang Ying; R Oktay Kacmaz; Pichaporn Artornsombudh; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; C Stephen Foster
Journal:  Ocul Immunol Inflamm       Date:  2016-03-22       Impact factor: 3.070

Review 10.  Adalimumab for orbital myositis in a patient with Crohn's disease who discontinued infliximab: a case report and review of the literature.

Authors:  Sanam Verma; Karen I Kroeker; Richard N Fedorak
Journal:  BMC Gastroenterol       Date:  2013-04-04       Impact factor: 3.067
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.